Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arne Kristian Skulberg

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Clinical Toxicology (Philadelphia, Pa.)|May 27, 2025
Nitazenes: review of comparative pharmacology and antagonist actionMarcus Stangeland, Ola Dale, Arne Kristian Skulberg
European Journal of Clinical Pharmacology|July 30, 2021
The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteersIda Tylleskar, Sissel Skarra, Arne Kristian Skulberg, et al.
European Journal of Clinical Pharmacology|August 26, 2018
Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanilIda Tylleskar, Arne Kristian Skulberg, Sissel Skarra, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|September 27, 2019
Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 studyIda Tylleskar, Arne Kristian Skulberg, Turid Nilsen, et al.
Resuscitation Plus|July 24, 2025
A chain of survival for drug overdoseMatthew Robert Dernbach, Nabarun Dasgupta, Adams L Sibley, et al.
European Journal of Clinical Pharmacology|February 2, 2017
Pharmacokinetics of a new, nasal formulation of naloxoneIda Tylleskar, Arne Kristian Skulberg, Turid Nilsen, et al.
Addiction (Abingdon, England)|January 16, 2019
Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trialArne Kristian Skulberg, Anders Åsberg, Hasse Zare Khiabani, et al.
European Journal of Clinical Pharmacology|March 24, 2018
Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteersArne Kristian Skulberg, Ida Tylleskar, Turid Nilsen, et al.
Substance Abuse|June 28, 2018
Ambulance-attended opioid overdoses: An examination into overdose locations and the role of a safe injection facilityDesiree Madah-Amiri, Arne Kristian Skulberg, Anne-Cathrine Braarud, et al.
Drug and Alcohol Dependence|July 7, 2026
A pilot randomized feasibility clinical trial of intranasal vs. intravenous naloxone in pediatric opioid poisoningNarges Gholami, Arne Kristian Skulberg, Fariba Farnaghi, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Clinical Toxicology (Philadelphia, Pa.)|May 27, 2025
Nitazenes: review of comparative pharmacology and antagonist actionMarcus Stangeland, Ola Dale, Arne Kristian Skulberg
European Journal of Clinical Pharmacology|July 30, 2021
The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteersIda Tylleskar, Sissel Skarra, Arne Kristian Skulberg, et al.
European Journal of Clinical Pharmacology|August 26, 2018
Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanilIda Tylleskar, Arne Kristian Skulberg, Sissel Skarra, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|September 27, 2019
Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 studyIda Tylleskar, Arne Kristian Skulberg, Turid Nilsen, et al.
Resuscitation Plus|July 24, 2025
A chain of survival for drug overdoseMatthew Robert Dernbach, Nabarun Dasgupta, Adams L Sibley, et al.
European Journal of Clinical Pharmacology|February 2, 2017
Pharmacokinetics of a new, nasal formulation of naloxoneIda Tylleskar, Arne Kristian Skulberg, Turid Nilsen, et al.
Addiction (Abingdon, England)|January 16, 2019
Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trialArne Kristian Skulberg, Anders Åsberg, Hasse Zare Khiabani, et al.
European Journal of Clinical Pharmacology|March 24, 2018
Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteersArne Kristian Skulberg, Ida Tylleskar, Turid Nilsen, et al.
Substance Abuse|June 28, 2018
Ambulance-attended opioid overdoses: An examination into overdose locations and the role of a safe injection facilityDesiree Madah-Amiri, Arne Kristian Skulberg, Anne-Cathrine Braarud, et al.
Drug and Alcohol Dependence|July 7, 2026
A pilot randomized feasibility clinical trial of intranasal vs. intravenous naloxone in pediatric opioid poisoningNarges Gholami, Arne Kristian Skulberg, Fariba Farnaghi, et al.
Pageof 2